4.7 Review

ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

期刊

AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 109, 期 7, 页码 950-966

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2014.131

关键词

-

资金

  1. Boehringer Ingleheim
  2. Abbvie
  3. Aegerion
  4. Salix
  5. BMS
  6. Lilly
  7. Cumberland Pharmaceuticals
  8. Intercept Pharmaceuticals
  9. Gilead
  10. Galectin Pharmaceuticals
  11. Alnylam
  12. Clinuvel
  13. Merck
  14. US National Institutes of Health (NHLBI, NIDDK)
  15. Vertex
  16. Novartis
  17. Anadys
  18. BI
  19. Cumberland
  20. Ocera

向作者/读者索取更多资源

Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction and it can lead to jaundice, liver failure, or even death. Antimicrobials and herbal and dietary supplements are among the most common therapeutic classes to cause DILI in the Western world. DILI is a diagnosis of exclusion and thus careful history taking and thorough work-up for competing etiologies are essential for its timely diagnosis. In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis and management of DILI with special emphasis on DILI due to herbal and dietary supplements and DILI occurring in individuals with underlying liver disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据